(Boursier.com) — MaaT Pharmaa French late-stage biotechnology company, a pioneer in the development of dedicated Microbiome Ecosystem Therapies (MET) to improve the survival of cancer patients, announces today that promising clinical data related to its two drug candidates, MaaT013 and MaaT033, will be the subject of two oral presentations by Pr. Florent Malard, professor of hematology at Saint-Antoine Hospital and Sorbonne University, during the 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT 2023) to be held April 23-26, 2023, in a hybrid format in Paris, France.
The EBMT annual meeting, a leading event in Europe, is dedicated to sharing very high-level scientific content in the field of transplantation and cell therapy. Oral presentations will present data previously shared at the American Society of Hematology Congress in December 2022.
Main clinical results obtained with MaaT013 within the framework of the compassionate access program in France (Early Access Program or “EAP”) in 81 patients treated
The clinical results demonstrated an overall response rate (GI-ORR) of 56%, including 30 patients in complete response (37%), 11 patients in very good partial response (14%) and 4 patients in partial response (5% ) in patients with GI-aGvH 28 days after treatment initiation; overall survival at 12 months was 59% in patients who responded to treatment with MaaT013.
An overall response rate of 65% was observed in 31 patients treated with MaaT013 as 3rd line treatment, after failure of 2nd line treatment with ruxolitinib. In this group that responded to treatment with MaaT013, the 12-month survival rate was 74%. A similar patient population is currently receiving treatment in MaaT Pharma’s ongoing pivotal Phase 3 ARES clinical trial in Europe.
©2023 Boursier.com